Partnership Strategy  Arisaph’s strong medicinal chemistry expertise and the Company’s proprietary drug discovery platforms represent important assets for the Company that can be leveraged through various business development arrangements.  The Company’s business development strategy seeks to leverage these assets through the following mechanisms:

1.       Drug discovery partnerships.  In these partnerships, Arisaph discovers and designs new compounds that address select and validated targets and the partner screens such compounds for proof-of-concept efficacy.  In this manner, Arisaph is able to leverage its competencies in an extremely focused manner without having to conduct significant basic research to identify a target, which is often time-consuming, expensive and risky.  Moreover, this partnership strategy also expands Arisaph’s therapeutic field and will help fuel the growth of the Company. 

2.       Research Collaborations.  In establishing the differentiated attributes of various drug candidates that Arisaph is developing internally, the Company may often form collaborations with academic or research institutions.  In such collaborations, Arisaph will leverage its drug discovery capabilities to design differentiated drug candidates and the research institution would screen such compounds for effectiveness on appropriate targets.   Such collaborations leverage the strengths of each party.  Once viable lead candidates have been identified, Arisaph will progress the development of the compound on its own or through co-development partnerships or direct out-licensing.       

3.       Out-licensing or co-development partnerships. Possessing important data demonstrating viability of a lead candidate, Arisaph will also explore the possibility of out-licensing or co-developing viable drug candidates that the Company has discovered internally.  Such strategy will leverage the partner’s skills and resources to conduct time-consuming and expensive clinical studies, while Arisaph participates in the expected value creation through anticipated royalty and milestone payments.